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The Incidence of Senile Cataract 
and Glaucoma is Increased 
in Patients with Plasma Cell 
Dyscrasias: Etiologic Implications
Kari Hemminki1,2, Asta Försti1,2, Raimo Tuuminen3, Otto Hemminki4,5, 
Hartmut Goldschmidt6,7, Kristina Sundquist2,8, Jan Sundquist2,8 & Xinjun Li2
Plasma cell dyscrasias, including monoclonal gammopathy of undetermined significance (MGUS), 
multiple myeloma (MM), Waldenström macroglobulinemia (WM) and light chain AL amyloidosis, are 
characterized by clonal expansion of plasma cells which produce a vast amount of an immunoglobulin-
derived M-protein. We noted that MGUS diagnosis often coincided with diagnoses of senile cataract 
and glaucoma and tested the associations of MGUS, MM, WM and AL amyloidosis with subsequent eye 
diseases identified from the Swedish patient registers between 1997 and 2012. Standardized incidence 
ratios (SIRs) for senile cataract was significantly increased to 1.80 after MGUS, 1.70 after MM, 1.85 
after WM and 2.31 after AL amyloidosis. The SIR for glaucoma was 1.60 after MGUS, 1.76 after WM 
and 2.18 after AL amyloidosis. All SIRs decreased systematically from age below 60 years to over 79 
years, but most risks were also significant in age group over 79 years. The M-protein and the related 
increase in blood viscosity could be a novel etiologic discovery for these common eye diseases. As MGUS 
prevalence is around 3% at 60 years and close to 10% at age over 80 years, its contribution to the eye 
disease burden is expected to be remarkably high.
Senile cataract and glaucoma are common diseases, the incidence of which increases steeply past the age of 
60 years1,2. Both of the diseases are the major causes of blindness worldwide, cataract being the leading one3. 
Among Swedes older than 39 years of age, 9.0% were diagnosed with cataract and 2.8% with glaucoma during a 
period of 11 years4. Senile cataract is defined as the opacity of the lens of the eye or its capsule, with no obvious 
cause, occurring in people over the age of 50 years5. The opacity is due to protein aggregates that are formed for 
unknown reasons. Protein aggregates may be located in various parts of the lens structure, which constitute the 
types of cataract: nuclear, cortical and posterior subcapsular6. The nuclear type is the most common one but in 
many patients mixed types are found1. There are some risk factors that facilitate the age dependent opacification, 
including family history, diabetes, smoking and solar exposure1,6. The composition of the lens opacity is not 
known but structural modifications of crystallins (the proteins maintaining the transparency of the lens) are sus-
pected to be involved and catalyzed by oxidative stress7,8. Glaucoma is a type of optic neuropathy characterized 
by indented appearance of the optic nerve, referred to as optic nerve cupping9. The cupping is a sign of damage to 
the optic nerve, which is often related to increased intraocular pressure. The cause of the elevated pressure may 
result from obstruction of the humoral drainage through the trabecular meshwork in the iridocorneal angle5. 
The main type of glaucoma is primary open-angle glaucoma in which the iridocorneal angle appears to be open 
as normal but the aqueous outflow may be obstructed; in the angle-closure glaucoma, however the drainage is 
usually blocked by the iris10.
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We have had an interest, prior to commencing this study, in genetics and epidemiology of plasma cell dyscra-
sias, including multiple myeloma (MM), monoclonal gammopathy of undetermined significance (MGUS) and 
light chain AL amyloidosis11–13. MGUS is a pre-malignant precursor condition of MM, AL amyloidosis and, 
additionally, of Waldenström macroglobulinemia (WM) with a combined progression rare of 1% per year14–16. 
The prevalence of MGUS increases almost linearly with age (after 50 years) reaching 9.9% in the age group 80 to 
89 years17. As MGUS is an asymptomatic condition it is diagnosed, often fortuitously, during a medical check-up 
for another cause, through serum paraprotein (M-protein) produced by a plasma cell clone14,18. We recently 
identified 11,233 MGUS patients from Swedish nationwide hospital records. Whilst in checking for other diag-
noses, rendered synchronously with MGUS, we found that senile cataract and glaucoma were surprisingly more 
common than expected. We present here the detailed incidence relationship with plasma cell dyscrasia and these 
eye diseases, and suggest that they may open a novel etiologic window into mechanisms of senile cataract and 
glaucoma.
Results
The numbers of people with the diagnosis of interest found in the Swedish medical registers are shown in Table 1. 
They range from 736,789 for senile cataract to 1530 for WM. Men outnumbered women for plasma cell dyscra-
sias, while the opposite was true for the eye diseases.
AL amyloidosis was diagnosed earlier (65 years) than the other conditions (72 to 76 years). The Outpatient 
Register was the main source of data for non-malignant conditions. Important for the uniformity of the follow-up 
period that 97% of senile cataract and 93% glaucoma data were obtained from the Outpatient Register covering 
years 2001 to 2012.
The suspected excess of senile cataract and glaucoma in plasma cell dyscrasia patients was entirely due to eye 
diseases diagnosed after the diagnoses of plasma cell dyscrasias. Thus all the following results refer to subsequent 
eye diseases.
In Table 2 subsequent risks of senile cataract are shown in plasma cell dyscrasia patients by sex, age at diag-
nosis of plasma cell dyscrasias and diagnosis defined by the third digit of the ICD-10 code. For all senile cataract 
the SIRs were between 1.70 and 1.85 after MGUS, MM and WM but higher (2.31) after AL amyloidosis. Male 
SIRs tend to be higher than female SIRs but none of the differences were significant (i.e., 95%CIs overlapped). All 
SIRs decreased systematically from age below 60 years to over 79 years. However, the decrease was less steep for 
MGUS than for the other plasma cell dyscrasias; the SIR was 7.30 in AL amyloidosis patients diagnosed at age 
below 60 years. Notably, all significant overall risks were also significant in age group over 79 years. Senile cata-
ract diagnoses were further refined by the third digit of the ICD-10 code. Although many of the diagnoses were 
non-specific, senile nuclear cataract was increased after all plasma cell dyscrasias (after WM and AL amyloidosis 
of borderline significance, i.e., the lower 95%CI was close to 1.00). An important support to the diagnostic accu-
racy was that among senile cataract patients 69% had at least two visits with the same diagnosis. No reliable data 
on eye operations were available.
In Table 3 subsequent risks of glaucoma are shown in plasma cell dyscrasias by sex, age at diagnosis of plasma 
cell dyscrasias and diagnosis defined by the third digit of the ICD-10 code. The SIRs were significantly increased 
after all plasma cell dyscrasias, with the exception of MM patients. However, the SIRs for glaucoma were some-
what lower than those after senile cataract: 1.60 after MGUS, 1.76 after WM and 2.18 after AL amyloidosis. Yet 
the distributions by sex and diagnostic age were similar for the two eye diseases; the SIR for glaucoma was 7.64 
in AL amyloidosis patients diagnosed at age below 60 years. Primary open-angle glaucoma was increased in both 
MGUS and AL amyloidosis patients. Some subcategories of glaucoma were vastly increased in AL amyloido-
sis patients, particularly for ‘glaucoma secondary to eye inflammation’ (N = 7, SIR 43.75, 95%CI 17.34–90.65). 
Among glaucoma patients, 73% had at least two visits with the same diagnosis and according to the data available 
from the Prescription Drug Register for years 2005 and 2012, 68% had received glaucoma medication.
Figure 1 shows the incidence of subsequent senile cataract and glaucoma in MGUS patients, compared to 
those without MGUS. For senile cataract (1711 with MGUS and 735,078 without MGUS) the incidence dif-
ference became apparent at age 40 years (Fig. 1A). At the maximum, at age 80 to 84 the incidence was almost 
doubled with MGUS background (6797 vs. 3845 per 100,000). For glaucoma (512 with MGUS and 298,910 with-
out MGUS), a clear incidence difference was noted from age 50 onwards depending on the MGUS background 
(Fig. 1B). The incidence data on senile cataract and glaucoma after MM, WM and AL amyloidosis are shown 
in Supplementary Figures 1 to 3. For senile cataract the incidence rates was clearly higher after all plasma cell 
dyscrasias; for glaucoma the differences were smaller and for MM there was no difference. The highest recorded 
MGUS MM Waldenström AL amyloidosis Senile cataract Glaucoma
Total 11,233 9666 1530 3538 736,789 299,122
Gender, males (%) 5766 (51%) 5300 (55%) 907 (59%) 1899 (54%) 283,883 (39%) 122,371 (41%)
Median diagnosis age 72 72 74 65 76 74
Data origin
 Cancer Registry 9666 1530
 Hospital Diagnosis Register 1895 2204 18,454 19,730
 Outpatient Register (%) 9338 (83%) 1334 (38%) 718,335 (97%) 279,392 (93%)
Table 1.  Number of cases, sex, median diagnosis age and origin of data for plasma cell dyscrasia and eye 
disease patients. MGUS: Monoclonal gammopathy of undetermined significance; MM: Multiple myeloma.
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incidence was after AL amyloidosis, 7514 per 100,000 in senile cataract, and 2252 per 100,000 for glaucoma 
(Supplementary Figure 3). Some 15% of the combined number of senile cataract and glaucoma patients were 
diagnosed with both diseases in the current population.
In Supplementary Table 1, subsequent risk of senile cataract and glaucoma are shown by follow-up time 
from the diagnosis of plasma cell dyscrasia and age at diagnosis of the eye disease. The SIRs of senile cataract 
and glaucoma showed a U-shaped relationship to the length of the follow-up time. The highest risks were in 
the year following plasma cell dyscrasia diagnosis and 10 or more years after diagnosis. The SIRs were higher 
when senile cataract and glaucoma were diagnosed before the age of 60 years compared to a later diagnosis. 
For senile cataract or glaucoma following AL amyloidosis before age 60 years, the SIRs were 7.30 and 7.64, 
respectively.
Discussion
The present results show convincing excess risk for subsequent senile cataract and glaucoma after four plasma 
cell dyscrasias, all of which are characterized by overproduction of immunoglobulin derived M-protein or light 
chains. In MGUS, the concentration is less than 3 g/dL and in MM it is above this limit. In WM, the M-protein is 
IgM at any increased concentration. In AL amyloidosis, the light chain is aggregated into amyloid particles. There 
are hardly any common risk factors, in addition to age, shared by plasma cell dyscrasias and the above mentioned 
eye diseases. A prolonged use of corticosteroids is a risk factor for senile cataract and glaucoma but no such 
medications are used in asymptomatic MGUS. Plasma cell dyscrasias show familial clustering but these are not 
known to encompass the studied eye diseases19. Thus the likely cause for the increased risk of senile cataract and 
glaucoma in plasma cell dyscrasia patients is the presence of the M-protein, which contributes to an increased 
viscosity of blood.
It has been estimated in the USA that an elevated level of M-protein is detectable on average more than 
10 years before the diagnosis of MGUS20. As MGUS is a precursor condition for the other present plasma cell 
dyscrasias, the affected individuals may experience an increased M-protein concentration for some decades. High 
concentrations of M-protein increase the viscosity of blood, and plasma cell dyscrasias may be diagnosed as a 
hyperviscosity syndrome21. The type of M-protein influences viscosity and the large size of IgM helps to confer 
a higher intrinsic viscosity compared to IgG and IgA. This is the reason why hyperviscosity is more prevalent in 
WM, overexpressing only IgM, than in MM, overexpressing most commonly IgG. In the present study the risks 
were quite uniform following MGUS, MM or WM, which may be due to lower medical attention or less active 
notification of multiple medical conditions in patients with important primary disease (MM and WM). Eye dis-
eases were most common in AL amyloidosis patients probably because amyloid aggregates would be expected to 
interfere with lens structures and eye fluid drainage systems. AL amyloidosis patients had a particularly high risk 
(43.75) for ‘glaucoma secondary to eye inflammation’, probably because of amyloids causing chronic irritation of 
the eye22,23.
A few personal risk factors of MGUS include black race, autoimmune disease, prior infections or exposure 
to herbicides24–26. MGUS is associated with the risk of bone fractures and of arterial and venal thrombosis27,28. 
A study in the Mayo clinic collected all medical diagnoses of 605 MGUS patients and compared these to local 
controls29. The associated diseases included plasma cell dyscrasias, superficial thrombophlebitis and bone dis-
eases, such as vertebral and hip fractures as well as osteoporosis. In the appendix of that paper, the relative risk of 
senile cataract was given as 1.1 (N = 25) and that of primary open-angle glaucoma as 1.1 (N = 33)29. An immi-
nent question is why the risk for these eye diseases was found significant only in the present study. One relevant 
point is that in the present study an increased risk for senile cataract and glaucoma was observed only following 
the four plasma cell dyscrasias, while in the cohort examined by Bida et al. the order of diagnoses is not clear29. 
MGUS MM Waldenström AL amyloidosis
O SIR 95% CI O SIR 95% CI O SIR 95% CI O SIR 95% CI
All 1711 1.80 1.71 1.88 891 1.70 1.59 1.81 237 1.85 1.63 2.11 338 2.31 2.07 2.57
Gender
 Men 771 1.80 1.67 1.93 439 1.80 1.64 1.98 132 1.91 1.60 2.27 161 2.50 2.13 2.92
 Women 940 1.80 1.68 1.91 452 1.61 1.46 1.76 105 1.78 1.46 2.16 177 2.16 1.85 2.50
Age at diagnosis (years)
 < 60 32 2.04 1.40 2.89 30 3.17 2.14 4.53 5 3.31 1.04 7.79 40 7.30 5.21 9.95
 60–79 967 1.88 1.76 2.00 536 1.77 1.63 1.93 137 2.10 1.77 2.49 215 2.29 1.99 2.62
 80+ 712 1.68 1.56 1.81 325 1.53 1.37 1.71 95 1.55 1.26 1.90 83 1.77 1.41 2.19
Subtype
  Senile incipient cataract (H25.0) 282 1.80 1.59 2.02 151 1.64 1.39 1.93 43 1.93 1.40 2.60 61 2.59 1.98 3.33
  Senile nuclear cataract (H25.1) 111 1.75 1.44 2.11 53 1.45 1.08 1.89 16 1.70 0.97 2.76 15 1.70 0.95 2.81
  Other senile cataract (H25.2, H25.8) 28 1.88 1.25 2.71 20 2.11 1.29 3.26 3 1.36 0.26 4.02 10 4.20 2.00 7.76
  Senile cataract, unspecified (H25.9) 1290 1.80 1.70 1.90 667 1.73 1.60 1.86 175 1.86 1.60 2.16 252 2.26 1.99 2.56
Table 2.  Subsequent risks of senile cataract in MGUS, MM, Waldenström, and AL amyloidosis patients. 
MGUS: Monoclonal gammopathy of undetermined significance; MM: Multiple myeloma. O = Observed cases; 
SIR = Standardized incidence ratio; CI = Confidence intervals. Bold type: 95% confidence interval does not 
include 1.00.
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Moreover, it is possible the catchment of senile cataracts was not complete in the study by Bida et al. because only 
25 cases were found (4.1% of MGUS diagnoses), while in the present study the corresponding figure was 15.2% 
(1711/11233).
The lens of the eye is considered exquisitely sensitive to protein aggregation because the ambient protein 
concentration is the highest of any tissue and because the lens proteins are extremely long-lived7,30. Against this 
background it is somewhat surprising that conditions with increased blood viscosity or protein aggregation have 
not previously attracted formal studies in relation of cataract or glaucoma. However some case reports have 
appeared, including on ocular manifestations in MM with suggested immunoglobulin light chain deposition in 
ocular tissues22. Case reports of secondary glaucoma in MM patients have also been published and an author of a 
case report on a glaucoma patient with MGUS speculated that the patient might have developed a hypercoagula-
ble syndrome and obstructed blood flow to the optic nerve22,31. Recurrent subconjuctival and periorbital bleeding 
was reported in AL amyloidosis23.
The present nation-wide study has the advantage of large patient numbers and statistical power. The data 
were collected from various sources with different starting times which may introduce some heterogeneity to 
the results. However, most importantly, the overwhelming proportion of eye disease data (~95%) was obtained 
from a uniform source, the Outpatient Register. The weakness of this source was that operation data were largely 
missing. The statistical method was based on indirect standardization which is particularly efficient when small 
numbers are analyzed32. In the present analysis various subgroups were small justifying the use of indirect stand-
ardization. Even though many overall results were relatively uniform with SIRs below 2.0, there were clear trends 
by sex, diagnostic age and subgroups. Importantly, SIRs were increased for subsequent but nor for prior eye 
diseases.
The present results provide unique clues to the pathophysiologic mechanisms of senile cataract and glau-
coma, with indirect incrimination of high concentrations of M-protein facilitating lens opacification and 
obstruction of humoral drainage through the trabecular meshwork. In case of senile cataract, the results were 
homogeneous for the four plasma cell dyscrasia, with slightly higher risk after AL amyloidosis than the three 
others. The data were also consistent for glaucoma, except that MM was associated with no risk. MM, WM and 
AL amyloidosis are life-threatening diseases, and the excess eye diseases cause an additional illness burden for 
the patients. However, the findings on MGUS have main implications to the understanding of senile cataract 
and glaucoma etiology. As MGUS is underdiagnosed its contribution to the associated eye diseases is much 
larger than the results show at the first glance. With a true prevalence of 10%, by age 80 years, the population 
attributable fraction of MGUS in senile cataract and glaucoma would probably surpass any known causes. For a 
proper population level risk estimation, M-protein levels need to be measured in senile cataract and glaucoma 
patients.
The current recommendations for MGUS call for follow-up by serum electrophoresis, if the likelihood of pro-
gression to MM, WM or AL amyloidosis is high14. The risk stratification considers M-protein concentration and 
type14. Most of the diagnosed cases are low-risk individuals who would not be followed-up after a control electro-
phoresis has shown a stable M-protein concentration. It is unlikely that the risk of senile cataract and glaucoma 
would change the recommendations for follow-up. However, a number of other diseases have also been associated 
with MGUS, including bone diseases, neuropathy and thrombosis27–29. With all these health risks associated with 
MGUS an active follow-up would be justified if efficient and risk-free interventions were available. The paradigm 
in oncology is to remove or destroy the precursor lesion before the transformation to malignancy or metastatic 
MGUS MM Waldenström AL amyloidosis
O SIR 95% CI O SIR 95% CI O SIR 95% CI O SIR 95% CI
All 512 1.60 1.47 1.75 207 1.11 0.97 1.28 81 1.76 1.40 2.19 118 2.18 1.81 2.62
Gender
 Men 227 1.59 1.39 1.81 100 1.13 0.92 1.38 48 1.94 1.43 2.57 62 2.49 1.91 3.19
 Women 285 1.61 1.43 1.81 107 1.10 0.90 1.33 33 1.55 1.07 2.18 56 1.92 1.45 2.50
Age at diagnosis (years)
 < 60 22 1.80 1.13 2.73 12 1.54 0.79 2.69 4 3.20 0.83 8.27 36 7.64 5.35 10.59
 60–79 283 1.66 1.47 1.86 120 1.13 0.93 1.35 41 1.76 1.26 2.39 55 1.60 1.20 2.08
 80+ 207 1.52 1.32 1.74 75 1.05 0.82 1.31 36 1.67 1.17 2.31 27 1.82 1.20 2.65
Subtype
 Glaucoma suspect (H40.0) 248 1.78 1.56 2.01 83 1.09 0.87 1.36 38 2.12 1.50 2.91 40 1.63 1.16 2.22
 Primary open-angle glaucoma (H40.1) 182 1.35 1.16 1.56 84 1.01 0.81 1.26 29 1.38 0.93 1.99 45 2.01 1.46 2.69
 Primary angle-closure glaucoma (H40.2) 8 1.85 0.79 3.66 2 0.73 0.07 2.69 1 1.59 0.00 9.10 1 1.27 0.00 7.26
 Glaucoma secondary to other eye disorders (H40.5) 16 2.25 1.28 3.66 9 2.12 0.96 4.04 2 1.80 0.17 6.63 10 8.47 4.04 15.64
 Other glaucoma (H40.3, H40.4, H40.6, and H40.8) 4 2.45 0.64 6.35 1 0.95 0.00 5.46 0 9 26.47 12.00 50.47
 Glaucoma, unspecified (H40.9) 54 1.66 1.25 2.17 28 1.46 0.97 2.11 11 2.10 1.04 3.78 13 2.74 1.45 4.70
Table 3.  Subsequent risks of glaucoma in MGUS, MM, Waldenström, and AL amyloidosis patients. 
MGUS: Monoclonal gammopathy of undetermined significance; MM: Multiple myeloma. O = Observed cases; 
SIR = Standardized incidence ratio; CI = Confidence intervals. Bold type: 95% confidence interval does not 
include 1.00.
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spread has occurred. The imminent challenge in MGUS research is to find ways of selectively and safely targeting 
the still benign M-protein producing plasma cell clone.
Patients and Methods
Persons diagnosed with MGUS, AL-amyloidosis, senile cataract and glaucoma were identified from the Swedish 
Hospital Discharge Register from 1997 through 2012, and the Outpatient Register from 2001 through 2012 
(Table 1). Both registers are nationwide. Only the first diagnosis for each person of MGUS, AL amyloidosis, senile 
cataract or glaucoma in either register was included. MM and WM were obtained from the Swedish Cancer Registry 
from the period 1997 through 2012. The International Classification of Diseases (ICD) version 10 was used to iden-
tify MGUS (D47.2), MM (C90), WM (C88), senile cataract (H25) and glaucoma (H40). The standard diagnostic 
criteria for MGUS was the presence of M-protein in serum at less than 3 g/dL, fewer than 10% plasma cells in the 
bone marrow, no evidence of other lymphoproliferative disorders, and lack of symptoms in relation to the monoclo-
nal gammopathy33. AL amyloidosis was defined by codes E85.4, E85.8 and E85.9. In addition, these patients had to 
be treated with melphalan, with data recorded in the Prescription Drug Register (in operation since 2005) because 
the diagnostic codes for AL amyloidosis were not specific as discussed34. Information from the registers was linked 
at the individual level using the national civic registration number, allowing practically a complete linkage to for 
the entire population. In the linked dataset, the number was replaced with a serial number to ensure anonymity.
Person-years were calculated from the start of follow-up on January 1st 1997/2001 until diagnosis of the rel-
evant disease, death, emigration, or the end of the study (December 31st, 2012) whichever came first. We used 
SAS version 9.3 for the statistical analyses. Standardized incidence ratios (SIRs) were calculated as the ratio of 
observed to expected number of cases, for the eye diseases between 1997 and 2012. The expected numbers were 
calculated for all individuals without a personal history of plasma cell dyscrasia. The rates were standardized 
by 5-year-age, gender, period (5-year-groups), socioeconomic status and residential area. The covariates were 
selected based on their known or assumed influence on the incidence of the diseases under study. Before adopting 
the full model they were individually added to the basic model which considered age and period only; however 
none of the added covariates essentially changed the risk estimates. The 95% confidence interval (95%CI) of 
the SIR was calculated assuming a Poisson distribution. The results are called statistically ‘significant’ when the 
95%CIs do not reach an SIR of 1.00.
Ethical statement. The study was approved by the Ethical Committee of Lund University and the study was 
conducted in accordance with the approved guidelines.
Figure 1. Incidence of subsequent senile cataract (A) and glaucoma (B) in MGUS patients compared to eye 
disease patients without prior MGUS.
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